Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study found that PLX, a mixture of tomato extract and chitooligosaccharide, may reduce prostate weight in testosterone-induced BPH in rats, suggesting it could act as a 5α-reductase inhibitor.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This paper presents a case where alopecia was associated with the use of escitalopram and improved after switching to duloxetine, alongside a literature review of antidepressant-related alopecia.

In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.

This study suggests that a topical emulsion containing Camellia sinensis and Allium cepa extracts may show promise for treating alopecia areata in Wistar rats.

This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.

This study indicated that administering letrozole to Swiss albino mice may have anticonvulsant effects against kainic acid-induced seizures by inhibiting testosterone aromatization to 17β-estradiol and increasing anticonvulsant metabolites in the hippocampus.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This case report documents an 8-year-old boy with alopecia areata presenting as symmetric alopecic patches with a triangular and targetoid pattern on the scalp, successfully treated with clobetasol propionate foam.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This article reviews the clinical characterization and potential treatments for androgenetic alopecia, highlighting minoxidil's efficacy in hair regrowth and noting the need for further genetic research; it reports no new clinical results.

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

This case report describes a unique instance of a 6-year-old girl developing angioedema after treatment with squaric acid dibutylester for alopecia areata.

The authors concluded that diazoxide reduces undesirable side effects compared to minoxidil while increasing elastic fiber content and decreasing cell number in the aorta, suggesting potential suitability for treating vascular conditions with low arterial elastin and hypertension.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This abstract describes a study that found fluoxetine HCl can be absorbed through cat skin when applied as a transdermal gel, though its bioavailability was about 10% compared to oral dosing.

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.

This article discusses treatments for androgenetic alopecia and alopecia areata, focusing on finasteride and minoxidil, and reports no new clinical results.

This article describes the DOAJ as a comprehensive index of diverse open access journals, emphasizing its commitment to freely providing quality content online, and reports no new findings.

Dutasteride injections can help treat hair loss in men and women.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This case study documents a boy with zinc-responsive acral hyperkeratosis improving significantly after zinc supplementation, suggesting it could result from inadequately treated acrodermatitis enteropathica.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study shares preliminary findings that roxithromycin treatment tendentially increased hair shaft production and altered the hair follicle microbiota in human hair ex vivo, with substantial inter-individual differences observed.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.